CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-30 | Quart Barry D Chief Executive Officer | Other acquisition | +1,607 | $13.22 | $21K | 69,600 |
| 2018-03-29 | TANG KEVIN C Director | Purchase | +192,308 | $26.00 | $5.0M | 8,525,215 |
| 2018-03-19 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +18,000 | $13.00 | $234K | 18,000 |
| 2018-03-19 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −18,000 | $30.00 | $540K | 0 |
| 2018-03-19 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Employee Stock Option (Right to Buy) | −18,000 | 94,416 | ||
| 2018-03-19 | Quart Barry D Chief Executive Officer | Exercise or conversion | +100,000 | $7.20 | $720K | 167,993 |
| 2018-03-19 | Quart Barry D Chief Executive Officer | Sale | −100,000 | $29.75 | $3.0M | 67,993 |
| 2018-03-19 | Quart Barry D Chief Executive Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −100,000 | 730,276 | ||
| 2018-03-14 | Quart Barry D Chief Executive Officer | Exercise or conversion | +100,000 | $7.20 | $720K | 167,993 |
| 2018-03-14 | Quart Barry D Chief Executive Officer | Sale | −100,000 | $24.75 | $2.5M | 67,993 |
| 2018-03-14 | Quart Barry D Chief Executive Officer | Exercise or conversion · Employee Stock Option(Right to Buy) | −100,000 | 830,276 | ||
| 2018-01-10 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +7,584 | $13.00 | $99K | 7,584 |
| 2018-01-10 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −7,584 | $20.00 | $152K | 0 |
| 2018-01-10 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Employee Stock Option (Right to Buy) | −7,584 | 112,416 | ||
| 2017-12-18 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2017-12-18 | POYHONEN JOHN Director | Grant or award · Stock Option (Right to Buy) | +19,500 | 19,500 | ||
| 2017-12-18 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2017-12-18 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +17,000 | 17,000 | ||
| 2017-12-18 | Rosen Robert President | Grant or award · Employee Stock Option (Right to Buy) | +310,000 | 310,000 | ||
| 2017-12-18 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +310,000 | 310,000 |
Page 33 of 38 · 746 trades